公开(公告)号：US20160194307A1

公开(公告)日：2016-07-07

申请号：US14915782

申请日：2014-09-02

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Louis S. Chupak ,  Xiaofan Zheng

IPC: C07D405/12 ,  C07D217/04 ,  C07C217/58 ,  C07D205/04 ,  C07C233/36 ,  C07D205/08 ,  C07D213/65 ,  C07C275/40 ,  C07D311/08 ,  C07C235/76 ,  C07D295/13 ,  C07D295/16 ,  C07D211/60 ,  C07D333/32

CPC classification number: A61K31/381 ,  A61K31/396 ,  A61K31/397 ,  A61K31/40 ,  A61K31/44 ,  A61K31/4427 ,  A61K31/445 ,  A61K31/4523 ,  A61K31/496 ,  A61K31/5375 ,  A61K31/55 ,  A61K31/551 ,  C07C217/58 ,  C07C229/14 ,  C07C229/22 ,  C07C233/36 ,  C07C233/38 ,  C07C233/47 ,  C07C233/78 ,  C07C235/76 ,  C07C237/06 ,  C07C255/54 ,  C07C271/20 ,  C07C275/40 ,  C07C279/12 ,  C07C279/14 ,  C07C311/05 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2602/08 ,  C07C2602/10 ,  C07D205/04 ,  C07D205/08 ,  C07D207/08 ,  C07D207/14 ,  C07D207/16 ,  C07D207/27 ,  C07D211/32 ,  C07D211/34 ,  C07D211/44 ,  C07D211/48 ,  C07D211/56 ,  C07D211/60 ,  C07D211/62 ,  C07D211/76 ,  C07D211/78 ,  C07D213/57 ,  C07D213/63 ,  C07D213/64 ,  C07D213/65 ,  C07D213/69 ,  C07D217/02 ,  C07D217/04 ,  C07D223/06 ,  C07D233/61 ,  C07D249/08 ,  C07D265/30 ,  C07D279/12 ,  C07D295/12 ,  C07D295/13 ,  C07D295/14 ,  C07D295/16 ,  C07D295/18 ,  C07D295/185 ,  C07D309/14 ,  C07D311/08 ,  C07D311/14 ,  C07D317/50 ,  C07D319/18 ,  C07D333/20 ,  C07D333/32 ,  C07D333/36 ,  C07D401/06 ,  C07D401/12 ,  C07D405/12 ,  C07D487/10 ,  C07K5/0806 ,  C07K5/0808

Abstract: Disclosed are compounds of Formula (I): (I). Also disclosed are methods of using such compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of virological diseases or disorders and cancer.

Abstract translation: 公开了式（I）的化合物：（I）。 还公开了使用这些化合物作为免疫调节剂的方法和包含这些化合物的药物组合物。 这些化合物可用于治疗，预防或减缓病毒学疾病或病症和癌症的发展。

公开(公告)号：US11866430B2

公开(公告)日：2024-01-09

申请号：US17254914

申请日：2019-06-26

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Louis S. Chupak ,  Min Ding ,  Robert G. Gentles ,  Yazhong Huang ,  Scott W. Martin ,  Ivar M. Mcdonald ,  Stephen E. Mercer ,  Richard E. Olson ,  Upender Velaparthi ,  Michael Wichroski ,  Xiaofan Zheng

IPC: C07D471/04 ,  A61K31/4375 ,  A61P35/00

CPC classification number: C07D471/04 ,  A61K31/4375 ,  A61P35/00

Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R3, and R4 are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK α) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

公开(公告)号：US20210277004A1

公开(公告)日：2021-09-09

申请号：US17254914

申请日：2019-06-26

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Louis S. Chupak ,  Min Ding ,  Robert G. Gentles ,  Yazhong Huang ,  Scott W. Martin ,  Ivar M. Mcdonald ,  Stephen E. Mercer ,  Richard E. Olson ,  Upender Velaparthi ,  Michael Wichroski ,  Xiaofan Zheng

IPC: C07D471/04 ,  A61P35/00

Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R3, and R4 are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK α) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

公开(公告)号：US10517870B2

公开(公告)日：2019-12-31

申请号：US15747218

申请日：2016-07-28

Applicant: Bristol-Myers Squibb Company

Inventor： Xiaojun Zhang ,  Xiaofan Zheng ,  Louis S. Chupak

IPC: A61K31/498 ,  C07D241/44 ,  A61P7/02 ,  A61P9/10 ,  A61P31/20

Abstract: Disclosed is a compound of Formula (I) or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein one R3 is H and the other R3 is an aryl group substituted with zero to 3 R3a; and R1, R2, and R3a are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors for the inhibition or prevention of platelet aggregation, and the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder. Also disclosed are methods of using such compounds for the treatment of human papillomavirus. Additionally, pharmaceutical compositions comprising at least one compound of Formula (I) are disclosed.